Newsroom

Takeda Corporate Information

To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/

Media Inquiries

Please contact us at US.corporatecommunications@takeda.com or (224) 554-5499.

Recent News Releases

April 2, 2019 4/2/2019 Motegrity™ (prucalopride), the Only Serotonin-4 Receptor Agonist for Adults with Chronic Idiopathic Constipation (CIC), is Now Available in the United States
March 18, 2019 3/18/2019 Takeda receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
January 11, 2019 1/11/2019 Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric® (febuxostat) Cardiovascular Outcomes Trial Results
October 26, 2018 10/26/2018 New Study Used Personalized Goals to Assess Treatment Effectiveness for Patients with Major Depressive Disorder
October 22, 2018 10/22/2018 New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder

SEE ALL NEWS AND RELEASES >

Copyright 2014-2018 Takeda Pharmaceutical Company Limited. All rights reserved.

Certified Top Employer

 

You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.